Tarsus Pharmaceuticals, Inc.
TARS
Rangering i aksjer
#4598
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aksjekurs
$71.12
Sist synkronisert: 2026-10-20
Markedsverdi
$3.33B
Endring (1 dag)
2.33%
Endring (1 år)
0.42%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Historikk for aksjesplitt for Tarsus Pharmaceuticals, Inc. (TARS)
Aksjen Tarsus Pharmaceuticals, Inc. (symbol: TARS) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én TARS-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 TARS-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én TARS-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 TARS-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
